Quick Answer
InMed Pharmaceuticals Inc. reported Net Income Loss of -$8.16 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed a decrease of -6.3% in Net Income Loss from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), InMed Pharmaceuticals Inc.'s Net Income Loss has grown by 8.7%.
- Historical annual values: Fiscal year 2025: -$8.16 million | Fiscal year 2024: -$7.68 million | Fiscal year 2023: -$7.95 million | Fiscal year 2022: -$18.60 million | Fiscal year 2021: -$10.20 million | Fiscal year 2020: -$8.94 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: